Loading…
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-27M | $-18M | $-23M | -87.0% | - | -38.0% |
| 2024 | $0M | $-28M | $-29M | $-18M | 32.3% | - | 69.5% |
| 2023 | $0M | $-17M | $-17M | $-21M | 28.0% | - | -15.6% |
| 2022 | $0M | $-20M | $-21M | $-18M | 45.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 21.19 | 18.66 | 28.11 | 26.75 |
| Research And Development | 18.47 | 15.87 | 23.65 | 18.01 |
| Selling General And Administration | 2.73 | 2.80 | 4.46 | 8.74 |
| Total Expenses | 21.19 | 18.66 | 28.11 | 26.75 |
| Operating Income | -21.19 | -18.66 | -28.11 | -26.75 |
| Total Operating Income As Reported | -21.19 | -18.66 | -28.11 | -26.75 |
| EBITDA | -20.45 | -17.25 | -28.01 | -26.65 |
| Normalized EBITDA | -20.45 | -17.25 | -28.01 | -26.65 |
| EBIT | -20.54 | -17.35 | -28.11 | -26.75 |
| Interest Income | 0.65 | 1.32 | 0.75 | 1.38 |
| Interest Expense | 0 | 0 | - | - |
| Net Interest Income | 0.65 | 1.32 | 0.75 | 1.38 |
| Other Non Operating Income Expenses | - | - | -2.04 | 7.16 |
| Other Income Expense | - | - | -2.04 | 7.16 |
| Interest Income Non Operating | 0.65 | 1.32 | 0.75 | 1.38 |
| Interest Expense Non Operating | 0 | 0 | - | - |
| Net Non Operating Interest Income Expense | 0.65 | 1.32 | 0.75 | 1.38 |
| Pretax Income | -20.54 | -17.35 | -29.40 | -18.21 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -20.54 | -17.35 | -29.40 | -18.21 |
| Net Income From Continuing And Discontinued Operation | -20.54 | -17.35 | -29.40 | -18.21 |
| Net Income From Continuing Operation Net Minority Interest | -20.54 | -17.35 | -29.40 | -18.21 |
| Net Income | -20.54 | -17.35 | -29.40 | -18.21 |
| Net Income Common Stockholders | -20.54 | -17.35 | -29.40 | -18.21 |
| Net Income Including Noncontrolling Interests | -20.54 | -17.35 | -29.40 | -18.21 |
| Normalized Income | -20.54 | -17.35 | -29.40 | -18.21 |
| Diluted NI Availto Com Stockholders | -20.54 | -17.35 | -29.40 | -18.21 |
| Basic Average Shares | 2.58 | 2.58 | 2.58 | 7.42 |
| Diluted Average Shares | 2.58 | 2.58 | 2.58 | 7.78 |
| Reconciled Depreciation | 0.08 | 0.10 | 0.10 | 0.10 |
| General And Administrative Expense | 2.73 | 2.80 | 4.46 | 8.74 |
| Other Gand A | 2.73 | 2.80 | 4.46 | 8.74 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tvardi Therapeutics, Inc.this co. | TVRD | $29M | -1.59 | 1.38 | -87.0% | -0.31 |
| DocGo Inc. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| aTyr Pharma, Inc. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| Myomo, Inc. | MYO | $50M | -3.20 | 4.37 | -136.6% | -4.36 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $46M |
| -2.09 |
| 5.86 |
| -280.5% |
| - |
| Accuray Incorporated | ARAY | $43M | -27.33 | 0.54 | -2.0% | 8.03 |
| Gossamer Bio, Inc. | GOSS | $42M | -0.24 | -0.34 | 138.8% | -1.31 |
| Tevogen Bio Holdings Inc. | TVGN | $41M | -1.57 | -2.42 | 154.2% | -1.89 |
| INmune Bio Inc. | INMB | $36M | -0.78 | 1.53 | -195.3% | -0.40 |
| Peer Median | - | -1.18 | 0.64 | -118.2% | -0.68 | |